Robert Olstein
Olstein Capital Management
Robert Olstein Medtronic PLC stake
total: 342
Olstein Capital Management MDT trades
- Total transactions:
- 36
- New positions:
- 1
- Sold out:
- 1
- Added:
- 15
- Reduced:
- 19
- Held since:
- 2014 Q2
- Held for:
- 48 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Robert Olstein doesn't hold any Medtronic PLC (MDT) shares. To date, the estimated cost basis is nearly $75.68 for "buy" trades and estimated average "sell" price is $88.34. Olstein Capital Management first purchased MDT in 2014 Q2, initially acquiring 115,000 shares. Since the initial investment in Medtronic PLC (MDT), Olstein Capital Management has made 35 more transactions.
When did Robert Olstein sell Medtronic PLC (MDT)?
Robert Olstein sold off the entire Medtronic PLC (MDT) position in 2026 Q2.
When did Robert Olstein buy Medtronic PLC (MDT)?
Robert Olstein first invested in Medtronic PLC (MDT) in 2014 Q2 at the reported quarter-end price of $63.76 per share.
What's the cost basis of Olstein Capital Management's MDT stake?
The estimated cost basis for Medtronic PLC (MDT) stake is around $75.68 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $75.68
- Weighted AVG sell price:
- $88.34
Robert Olstein's historical trades in Medtronic PLC
36 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.00%
|
0
|
$86.64
|
|
-100% (-73,000)
|
-1.38%
|
|
2025 Q4
|
1.44%
|
73,000
|
$96.05
|
$7,012,000
|
-16.09% (-14,000)
|
-0.25%
|
|
2025 Q3
|
1.56%
|
87,000
|
$95.24
|
$8,286,000
|
+3.57% (+3,000)
|
+0.05%
|
|
2025 Q1
|
1.39%
|
84,000
|
$89.86
|
$7,548,000
|
-10.64% (-10,000)
|
-0.16%
|
|
2024 Q4
|
1.32%
|
94,000
|
$79.88
|
$7,509,000
|
+8.05% (+7,000)
|
+0.1%
|
|
2024 Q3
|
1.33%
|
87,000
|
$90.03
|
$7,833,000
|
+19.18% (+14,000)
|
+0.21%
|
|
2024 Q2
|
1.02%
|
73,000
|
$78.71
|
$5,746,000
|
-28.43% (-29,000)
|
-0.37%
|
|
2023 Q4
|
1.42%
|
102,000
|
$82.38
|
$8,403,000
|
+2.00% (+2,000)
|
+0.03%
|
|
2022 Q4
|
1.22%
|
100,000
|
$77.72
|
$7,772,000
|
+29.87% (+23,000)
|
+0.28%
|
|
2022 Q2
|
1.04%
|
77,000
|
$89.75
|
$6,911,000
|
-23.76% (-24,000)
|
-0.27%
|
|
2022 Q1
|
1.40%
|
$110.95
|
-4.72% (-5,000)
|
|||
|
2021 Q4
|
1.31%
|
$103.45
|
+55.88% (+38,000)
|
|||
|
2021 Q3
|
1.04%
|
$125.35
|
-4.23% (-3,000)
|
|||
|
2021 Q2
|
1.11%
|
$124.13
|
-6.58% (-5,000)
|
|||
|
2020 Q4
|
1.42%
|
$117.14
|
-11.63% (-10,000)
|
|||
|
2020 Q2
|
1.47%
|
$91.70
|
+21.13% (+15,000)
|
|||
|
2020 Q1
|
1.40%
|
$90.18
|
+2.90% (+2,000)
|
|||
|
2019 Q4
|
1.21%
|
$113.45
|
-6.76% (-5,000)
|
|||
|
2019 Q2
|
1.17%
|
$97.39
|
+7.25% (+5,000)
|
|||
|
2019 Q1
|
1.04%
|
$91.09
|
+11.29% (+7,000)
|
|||
|
2018 Q4
|
0.92%
|
$90.97
|
-12.58% (-8,920)
|
|||
|
2018 Q3
|
0.93%
|
$98.36
|
-17.53% (-15,080)
|
|||
|
2018 Q2
|
0.98%
|
$85.60
|
-25.86% (-30,000)
|
|||
|
2018 Q1
|
1.18%
|
$80.22
|
-0.85% (-1,000)
|
|||
|
2017 Q4
|
1.20%
|
$80.75
|
+5.41% (+6,000)
|
|||
|
2017 Q3
|
1.11%
|
$77.77
|
+21.78% (+19,850)
|
|||
|
2017 Q2
|
1.03%
|
$88.75
|
-24.67% (-29,850)
|
|||
|
2017 Q1
|
1.25%
|
$80.56
|
+10.00% (+11,000)
|
|||
|
2016 Q4
|
1.01%
|
$71.23
|
+127.12% (+61,568)
|
|||
|
2016 Q3
|
0.55%
|
$86.41
|
-26.62% (-17,568)
|
|||
|
2016 Q2
|
0.77%
|
$86.77
|
-31.25% (-30,000)
|
|||
|
2016 Q1
|
0.96%
|
$75.00
|
-11.11% (-12,000)
|
|||
|
2015 Q4
|
1.07%
|
$76.92
|
-19.40% (-26,000)
|
|||
|
2014 Q4
|
1.18%
|
$72.20
|
-5.63% (-8,000)
|
|||
|
2014 Q3
|
1.15%
|
$61.95
|
+23.48% (+27,000)
|
|||
|
2014 Q2
|
0.99%
|
$63.76
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.